Alzheimer's Disease, Phase II-III

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)

Volunteers
Health Professionals

What is the purpose of this trial?

Visit the Alzheimer's Disease Research Unit (ADRU) here.

The purpose of this study is to assess the safety, tolerability and biomarker efficacy of Gantenerumab and Solanezumab in individuals who have an autosomal dominant Alzheimer's disease (ADAD) mutation.

Trial with
Washington University School of Medicine
Ages
18 years - 80 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Jeanine L. May

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Christopher van Dyck, MD
Elizabeth Mears and House Jameson Professor of Psychiatry and of Neurology and Neuroscience; Director, Alzheimer's Disease Research Unit; Director, Yale Alzheimer's Disease Research Center; Director, Division of Aging and Geriatric Psychiatry

Sub-Investigators

Last Updated
08/30/2024
Study HIC
#1308012526